Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma (BBIO) is a biopharmaceutical innovator developing genetic disease therapies through its unique portfolio-based approach. This page serves as the definitive source for official company announcements, clinical trial updates, and strategic developments.
Investors and stakeholders gain centralized access to critical updates including clinical milestones, regulatory filings, financial disclosures, and research partnerships. Our curated feed ensures timely tracking of therapeutic advancements across BridgeBio's diversified pipeline.
Key focus areas include progress in Mendelian disorder treatments, oncology targets, and gene therapy innovations. All content undergoes strict verification to maintain compliance with financial disclosure standards and medical accuracy guidelines.
Bookmark this page for efficient monitoring of BBIO's scientific advancements and corporate developments. Combine this resource with SEC filings and earnings transcripts for comprehensive investment analysis.
BridgeBio Pharma (Nasdaq: BBIO) and Venthera, Inc. presented preliminary data from the Phase 1b trial of VT30 topical gel, targeting venous and lymphatic lesions. The trial showed that VT30 was generally well-tolerated across 15 participants, with mild to moderate local rashes as the only notable adverse effect. Importantly, pharmacokinetic data indicated drug concentrations were sufficient within lesions, while no systemic drug was detected in plasma. Venthera plans to advance the 0.6% gel into further studies and is seeking development partners.
BridgeBio Pharma (BBIO) announced that preliminary data from a 24-week Phase 2b study of encaleret in treating autosomal dominant hypocalcemia type 1 (ADH1) will be presented at the Endocrine Society's Annual Conference on June 13, 2022. This data suggests that encaleret restores mineral homeostasis, marking a significant step in clinical research. Alongside this, comprehensive presentations on various programs, including achondroplasia and congenital adrenal hyperplasia, will also be discussed. An investor call is slated for the same day to focus on the Phase 2b data.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced participation in two key investor conferences. The Jefferies Healthcare Conference is scheduled for June 9 at 4:00 pm ET, followed by the Goldman Sachs Global Healthcare Conference on June 15 at 5:00 pm ET.
Live webcasts will be available on the BridgeBio Investors page. A replay will be accessible for 90 days post-event. Founded in 2015, BridgeBio focuses on developing transformative medicines targeting genetic diseases and cancers.
BridgeBio Pharma announced promising interim Phase 1 data for BBP-671, an investigational therapy targeting pantothenate kinase-associated neurodegeneration (PKAN) and organic acidemias. The study found BBP-671 in healthy volunteer plasma and cerebrospinal fluid, indicating its ability to cross the blood-brain barrier. Additionally, it elevated whole blood acetyl-CoA levels, demonstrating proof of mechanism. The company plans to advance to the next study phase for propionic acidemia and methylmalonic acidemia in late 2022 and initiate a pivotal study for PKAN in 2023.
BridgeBio Pharma, Inc. (BBIO) announced positive results from a Phase 2 trial of PTR-01, a recombinant collagen 7 protein replacement therapy for recessive dystrophic epidermolysis bullosa (RDEB). The treatment demonstrated rapid and consistent wound healing, with over 80% of wounds showing a significant reduction in size. Patients reported a 36% mean reduction in pain, and the therapy was well-tolerated over four months. The findings were presented at the Society for Investigative Dermatology Annual Meeting. Phoenix Tissue Repair has commenced a Phase 2 extension study for further evaluation.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced participation in several investor conferences. Key events include the Citi Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Panel on May 18 at 2:30 PM ET, and multiple sessions on May 24, including H. C. Wainwright Global Investment Conference at 7:00 AM ET, UBS Global Healthcare Conference at 11:30 AM ET, and J. P. Morgan West Coast Investor Day at 12:00 PM ET. For more details, visit the BridgeBio Investors page.
BridgeBio Pharma (BBIO) announced the sale of its Priority Review Voucher (PRV) for $110 million, following its acquisition in February 2021. The PRV was received after FDA approval of NULIBRY for treating molybdenum cofactor deficiency. The sale is subject to standard closing conditions. Additionally, the company secured a two-year extension on its interest-only period under its senior secured credit facility, delaying principal repayments to November 2026. These strategic moves aim to boost the development of drug programs targeting genetic diseases and cancers.
BridgeBio Pharma has secured an exclusive license with Bristol Myers Squibb for BBP-398, a SHP2 inhibitor aimed at treating challenging cancers. The deal includes an upfront payment of $90 million and potential total payments reaching $905 million from milestones and royalties. BridgeBio will continue leading ongoing clinical trials, while Bristol Myers Squibb will manage future development and commercialization. This collaboration aims to enhance treatment options for patients with advanced solid tumors, particularly those with KRAS mutations.
BridgeBio Pharma, a biopharmaceutical company focused on genetic diseases and cancers, announced its management team's participation in the Bank of America Securities Healthcare Conference on May 11, 2022, at 7:40 pm ET. Investors can access the live webcast on the 'Events & Presentations' page of BridgeBio's website, with a replay available for 90 days post-event. Founded in 2015, BridgeBio aims to develop transformative medicines for patients with genetic conditions, showcasing a commitment to genetic medicine.
BridgeBio Pharma reported significant updates, including the sale of NULIBRY™ to Sentynl Therapeutics and an updated collaboration with Helsinn Group for infigratinib. Positive Phase 2 data for BBP-418 showed a 43% increase in glycosylated alpha-dystroglycan in LGMD2i patients. The ongoing study of acoramidis in ATTR-CM patients continued to demonstrate well-tolerated results. Financially, the company ended Q1 with $633.5 million in cash, while restructuring efforts are expected to reduce expenses significantly. However, a net loss of $196.4 million was recorded.
FAQ
What is the current stock price of Bridgebio Pharma (BBIO)?
What is the market cap of Bridgebio Pharma (BBIO)?
